20240208171546.png)
New research from Memorial Sloan Kettering Cancer Center (MSK)& investigates how pancreatic cancer cells regulate their genome to avoid immune attack; shows promise against glioblastoma in mouse models; and develops a new method to study cancer evolution.
New MSK research marks a potential advance against RAS-driven cancers; breaks down data silos to better predict cancer outcomes with the help of artificial intelligence (AI); identifies two enzymes vital for maintaining brain health; uncovers how changes to 鈥渉elper鈥� proteins drive cancer cell survival; develops a new model for investigating lung cancer metastasis; and uses AI to improve outcome predictions in sarcoma.
Along with defending against pathogens, the body鈥檚 innate immune system helps to protect the stability of our genomes in unexpected ways 鈥� ways that have important implications for the development of cancer, researchers at MSK are discovering.
Ivan Maillard, MD, PhD, has been named Head of the Division of Hematologic Malignancies within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).
NEW YORK, October 31, 2024 鈥� Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:
Dr. Deb Schrag, Chair of the Department of Medicine, and Dr. Lorenz Studer, Director of the Center for Stem Cell Biology at Memorial Sloan Kettering Cancer Center (MSK), have been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.
New research from Memorial Sloan Kettering Cancer Center (MSK) uses saturation genome editing to better understanding of the RAD51C gene, which has been linked to higher risks of breast and ovarian cancer; sheds new light on brain metastasis; and finds a commercially available contrast dye could help surgeons better separate cancer from healthy tissue.
A team of doctors and researchers at MSK have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. Learn how one 19-year-old patient sparked a detective story.
Mark Awad, MD, PhD, has been appointed Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).
MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.
New research from Memorial Sloan Kettering Cancer Center (MSK) uses cryo-electron microscopy to shed new light on the ubiquitin; could help predict the risk of blood clots in cancer patients; reveals why micronuclei burst, accelerating aggressive cancers; and surveys healthcare providers about the benefits and risks of commercial genetic testing.
Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments
New research from Memorial Sloan Kettering Cancer Center (MSK) found patients with non-small cell lung cancer brain metastases may benefit from up-front stereotactic radiosurgery; identified a connection between antibiotic use and autoimmune diseases; and uncovered a previously unknown structural role for messenger RNAs in the cytoplasm of cells.
Memorial Sloan Kettering Cancer Center (MSK) announced the following awards and appointments.
New research from Memorial Sloan Kettering Cancer Center (MSK) showed giving chemotherapy shortly after a stem cell or bone marrow transplant from a less than perfectly matched donor greatly reduces the chances that the patient will develop聽graft-versus-host disease (GVHD); and sheds new light on cell state changes in prostate cancer.
In order for immune cells to effectively kill cancer cells, a triad of three cells are necessary 鈥� a dendritic cell, a cytotoxic 鈥渒iller鈥� T cell, and a helper T cell, researchers at MSK and Baylor College of Medicine have found. The discovery could alter the way doctors administer immunotherapies.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) have discovered a new mechanism of resistance to KRAS inhibitors that suggests an opportunity to make the treatment more effective.
Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation proudly announce that eight distinguished MSK nurses and one nursing team were honored with the 2024 Robbins Family Award for Nursing Excellence. The awards coincide with National Nurses Week (May 6 鈥� 12).
20240208171546.png&width=400&height=400)
Memorial Sloan Kettering Cancer Center (MSK) today announced an innovative set of initiatives to support underserved communities in New York City who lack access to cancer screening and early detection. With critical support from longtime MSK Board Member Bruce Ratner, the Ratner Early Detection Initiative (REDI) draws from MSK鈥檚 deep experience in cancer science and discovery, community engagement, and compassionate patient care.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Jeffrey A. Drebin, MD, PhD, has been named President-Elect of the American Surgical Association (ASA) for 2024.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right